Abstract: There is disclosed a process for rendering a labile protein-containing composition, substantially free of lipid-containing viruses without incurring substantial protein denaturation comprising contacting said composition with an effective amount of a fatty acid or a soluble ester, alcohol or a salt thereof for a sufficient period of time to inactivate virus contained therein.
Abstract: A mammalian blood protein-containing composition such as whole blood, plasma, serum, plasma concentrate, cryoprecipitate, cryosupernatant, plasma fractionation precipitate or plasma fractionation supernatant substantially free of hepatitis and other lipid coated viruses with the yield of protein activity to total protein being at least 80% is disclosed. The protein-containing composition is contacted with di- or trialkylphosphate, preferably a mixture of trialkylphosphate and detergent, usually followed by removal of the di- or trialkylphosphate.
Abstract: A method of removing lipid soluble process chemicals from biological materials containing the lipid soluble process chemicals comprising bringing the biological materials containing the lipid soluble process chemicals into contact with an effective amount of a naturally occurring oil extracted from a plant or an animal or a synthetic compound of similar chemical structure, agitating the resultant mixture, separating out an upper-phase and a lower-phase by sedimentation and decanting the upper-phase. The method is particularly useful for producing relatively virus free physiologically acceptable plasma.
Abstract: A process for predicting the sensitivity of cells, e.g., tumor cells, to the effects of tumor necrosis factor or lymphotoxin involving ascertaining the binding of the tumor necrosis factor or lymphotoxin to the cells, i.e., measuring the number of receptors on the cells.
Type:
Grant
Filed:
August 29, 1985
Date of Patent:
September 13, 1988
Assignees:
New York Blood Center, Inc, Sloan-Kettering Institute for Cancer Research
Inventors:
Berish Y. Rubin, Sylvia L. Anderson, Susan A. Sullivan, Lloyd J. Old, Barbara D. Williamson, Elizabeth C. Richards
Abstract: A mammalian blood protein-containing composition such as whole blood, plasma, serum, plasma concentrate, cryoprecipitate, cryosupernatant, plasma fractionation precipitate or plasma fractionation supernatant substantially free of hepatitis and other lipid coated viruses with the yield of protein activity to total protein being at least 80% is disclosed. The protein-containing composition is contacted with di- or trialkylphosphate, preferably a mixture of trialkylphosphate and detergent, usually followed by removal of the di- or trialkylphosphate.
Abstract: Hybridoma for production of monoclonal antibody to an antigen found on the peptide fragment of the B.beta. chain of human fibrinogen or fibrin I containing amino acid residues 1-42. The hybridoma is formed by fusing an animal myeloma cell, e.g., a mouse myeloma cell, with a splenocyte from an animal, e.g., a mouse, immunized with an NH.sub.2 -terminal of human fibrinogen or fibrin I. Hybridoma for production of monoclonal antibody to an antigen found on the peptide fragment of the B.beta. chain of human fibrin II containing amino acid residues 15-42. The hybridoma is formed by fusing an animal, e.g., mouse myeloma cell with a splenocyte from an animal, e.g., mouse, immunized with a NH.sub.2 -terminal of human fibrin II. Diagnostic and therapeutic uses of the monoclonal antibodies are also disclosed.
Abstract: There is disclosed a process for producing a proteinaceous mass containing particles of HBsAg in a morphological form not found in nature while inactivating any live virus contained therein. The process comprises subjecting a concentrated mass thereof free of protein diluent or a stabilizer to a heat inactivation by heating the same while in a concentration of at least 1 mg/ml at a temperature of 101.degree. to 105.degree. C. for 1 to 5 minutes and thereafter cooling the so heated particles.
Type:
Grant
Filed:
April 1, 1985
Date of Patent:
September 22, 1987
Assignees:
New York Blood Center, Inc., Eugene Tech International, Inc.
Abstract: There is disclosed a filter comprising fibrin in gel form, the gel having substantially uniform pore sizes, and the filter comprising means for retaining the shape of at least one surface of the gel against deformation when contacted by a flowing medium.
Abstract: There are disclosed a process for enhancing the immunogenicity of a lipid membrane based immunogen comprising flash heating it at a membrane concentrations sufficient under the conditions of flash heating to result in melting of membranes and fusing the melted membranes into novel morphologic forms and a proteinaceous mass comprising particles of HBsAg, said particles including particles of HBsAg in morphologic form not found in nature, said HBsAg contains particles being filaments, branched filaments, closed circular or closed circular branched filaments.
Abstract: There is disclosed a process for obtaining a protein-containing composition which is substantially free of lipid-containing viruses without incurring substantial protein denaturation comprising contacting said protein-containing composition with an effective amount of oleic acid, its ester or alkali or alkaline earth metal salt for a sufficient period of time to inactivate virus contained therein.
Abstract: Type O erythrocytes are produced from certain subtypes of A erythrocytes or type AB erythrocytes by contacting the same following equilibration of a pH of 5.6-5.8 with an .alpha.-N-acetylgalactosaminidase, preferably obtained from an avian liver, for periods sufficient to convert the A antigen in the erythrocyte to the H antigen. Following removal of the enzyme, the erythrocyte is re-equilibrated to a pH of 7.2-7.4. As a result, there is obtained O type erythrocytes characterized by a 60 to 90 percent ATP level based on the level of ATP in naturally occurring O or AB erythrocytes. Beginning with certain A cells one obtains synthetic O erythrocytes characterized by a terminal .alpha.-fucose moiety, O antigenicity, and the absence of A antigenicity. Beginning with A.sub.2 B erythrocytes, one obtains B erythrocytes by the same process characterized by the absence of A antigenicity, greater H antigenicity than naturally occurring A.sub.2 B cells, the presence of B antigenicity and the aforedescribed ATP levels.
Abstract: A composition having a protein binding solid support onto which is bound a mixture of antigens and antibodies which are both bound to the solid support individually and are not present in the form of an immune complex.
Abstract: A mammalian blood plasma or plasma derivative substantially free of active hepatitis B or non-A, non-B viruses is disclosed, the plasma being characterized by the presence of factor VIII, the percent by weight of denatured factor VIII to the sum of undenatured factor VIII and denatured factor VIII being less than 50%. The plasma is sterilized by contact with a detergent, alcohol or ether, and mixtures thereof and preferably a mixture of detergent and ether, usually followed by removal of the viral sterilizing agent.
Abstract: A radiolabeled or enzyme labeled peptide having no more than 60 amino acids in the chain of the peptide; the peptide having covalently linked amino acids disposed in a steric configuration which is recognized by and bound by an antibody. The labeled peptides can be utilized in various processes to detect the presence of a given antibody or antigen in a sample. Hepatitis B surface antigen and antibody to same may be so detected.
Abstract: There is disclosed a filter comprising fibrin in gel form, the gel having substantially uniform pore sizes, and the filter comprising means for retaining the shape of at least one surface of the gel against deformation when contacted by a flowing medium.
Abstract: There is disclosed a new synthetic peptide which evokes an immunological response. The synthetic peptide, moreover, interacts with antibodies to hepatitis B surface antigen (HBsAg). Thus, the synthetic peptide is useful as an immunizing agent in a vaccine as an active component thereof where it serves to produce antibodies in vivo which are protective against hepatitis B virus. The synthetic peptide of the invention comprises the following sequence of amino acids: Arg Trp Met Met Leu Arg Arg (I) and preferably has the following sequence: Gly Tyr Arg Trp Met Met Leu Arg Arg Phe Gly (II).
Type:
Grant
Filed:
May 12, 1983
Date of Patent:
March 25, 1986
Assignee:
New York Blood Center, Inc.
Inventors:
John Vnek, Alfred M. Prince, Hafeez Ikram
Abstract: There is disclosed a new synthetic peptide which evokes an immunological response. The synthetic peptide, moreover, interacts with antibodies to Hepatitis B surface antigen (HBsAG). Thus, the synthetic peptide is useful as an immunizing agent in a vaccine as an active component thereof where it serves to produce antibodies in vivo which are protective against Hepatitis B virus. The synthetic peptide of the invention comprises the following sequence of amino acids: Arg Trp Met Met Leu Arg Arg(I) and preferably has the following sequence: Gly Tyr Arg Trp Met Met Leu Arg Arg Phe Gly (II).
Type:
Grant
Filed:
July 17, 1984
Date of Patent:
March 11, 1986
Assignee:
New York Blood Center, Inc.
Inventors:
John Vnek, Alfred M. Prince, Hafeez Ikram
Abstract: An immunoglobulin is provided which consists essentially of a mono-specific, hetero-molecular antibody which is mono-specific to a single antigenic or allergenic determinant. The antibody is specific to the H-epitope of a protein antigen or allergen. The H-epitope is defined by a sequence of at least six amino acids corresponding to the sequence of such amino acids in the protein antigen or allergen where the greatest local average hydrophilicity of the protein antigen or allergen is found.
Abstract: A mammalian blood protein-containing composition such as whole blood, plasma, serum, plasma concentrate, cryoprecipitate, cryosupernatant, plasma fractionation precipitate or plasma fractionation supernatant substantially free of hepatitis and other lipid coated viruses with the yield of protein activity to total protein being at least 80% is disclosed. The protein-containing composition is contacted with di- or trialkylphosphate, preferably a mixture of trialkylphosphate and detergent, usually followed by removal of the di- or trialkylphosphate.
Abstract: There is disclosed a filter comprising fibrin in gel form, the gel having substantially uniform pore sizes, and the filter comprising means for retaining the shape of at least one surface of the gel against deformation when contacted by a flowing medium.